Skip to main content
SpringerLink
Log in

Study of the Neuroprotective Properties of Fullerenol C60(OH)30 with a Model of Alzheimer’s Disease

  • NANOBIOMEDICINE AND NANOPHARMACEUTICALS
  • Published:
Nanotechnologies in Russia Aims and scope Submit manuscript

Abstract

An urgent task of modern medicine is the search for drugs that can stop or slow down the course of neurodegenerative diseases, in particular Alzheimer’s disease. The aim of this work was to determine the effect of fullerenol C60(OH)30 on the pathogenesis of Alzheimer’s disease in the Drosophila melanogaster model. The effect of fullerenol on the life expectancy, the level of geotaxis, learning and memory, and the levels of neurodegeneration and reactive oxygen species in the animal brain was studied. Based on the results, it can be assumed that fullerenol C60(OH)30 is a promising agent for the development of complex therapy for Alzheimer’s disease.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1.
Fig. 2.
Fig. 3.
Fig. 4.
Fig. 5.
Fig. 6.

Similar content being viewed by others

REFERENCES

  1. S. Tiwari, V. Atluri, A. Kaushik, et al., Int. J. Nanomed. 14, 5541 (2019).

    Article  CAS  Google Scholar 

  2. C. A. Lane, J. Hardy, and J. M. Schott, Eur. J. Neurol. 25, 59 (2018).

    Article  CAS  Google Scholar 

  3. P. Marešová, H. Mohelská, J. Dolejš, and K. Kuča, Curr. Alzheimer Res. 12, 903 (2015).

    Article  Google Scholar 

  4. D. J. Selkoe, Behav. Brain Res. 192, 106 (2008).

    Article  CAS  Google Scholar 

  5. X. Q. Chen and W. C. Mobley, Front. Neurosci. 13, 659 (2019).

    Article  Google Scholar 

  6. E. Koseoglu, World J. Clin. Cases 7, 1764 (2019).

    Article  Google Scholar 

  7. A. G. Bobylev, L. G. Marsagishvili, M. D. Shpagina, V. S. Romanova, R. A. Kotelnikova, and Z. A. Podlubnaya, Biophysics 55, 353 (2010).

    Article  Google Scholar 

  8. A. G. Bobylev, Yu. V. Shatalin, I. M. Vikhlyantsev, L. G. Bobyleva, S. V. Gudkov, and Z. A. Podlubnaya, Biophysics 59, 685 (2014).

    Article  CAS  Google Scholar 

  9. Z. Bednarikova, P. D. Q. Huy, M. M. Mocanu, et al., Phys. Chem. Chem. Phys. 18, 18855 (2016).

    Article  CAS  Google Scholar 

  10. U. B. Pandey and C. D. Nichols, Pharmacol. Rev. 63, 411 (2011).

    Article  CAS  Google Scholar 

  11. L. McGurk, A. Berson, and N. M. Bonini, Genetics 201, 377 (2015).

    Article  CAS  Google Scholar 

  12. L. Tsuda and Y. M. Lim, Adv. Exp. Med. Biol. 1076, 25 (2018).

    Article  CAS  Google Scholar 

  13. A. Borisenkova, M. Suyasova, et al., Mater. Sci. Eng. C 104, 109945 (2019).

    Article  Google Scholar 

  14. M. Hirohata, K. Ono, J. Takasaki, et al., Biochim. Biophys. Acta 1822, 1316 (2012).

    Article  CAS  Google Scholar 

  15. K. Iijima, H. P. Liu, A. S. Chiang, et al., Proc. Natl. Acad. Sci. U. S. A. 101, 6623 (2004).

    Article  CAS  Google Scholar 

  16. A. H. Brand and N. Perrimon, Development 118, 401 (1993).

    CAS  Google Scholar 

  17. T. Tully and W. G. Quinn, J. Comp. Physiol. 157, 263 (1985).

    Article  CAS  Google Scholar 

  18. J. E. Kim and M. Lee, Biochem. Biophys. Res. Commun. 303, 576 (2003).

    Article  CAS  Google Scholar 

  19. Z. Chen and C. Zhong, Neurosci Bull. 30, 271 (2014).

    Article  CAS  Google Scholar 

  20. E. Tonnies and E. Trushina, J. Alzheimers Dis. 57, 1105 (2017).

    Article  Google Scholar 

  21. L. Cassidy, F. Fernez, J. B. Johnson, et al., Theor Med. 49, 102294 (2020).

    Google Scholar 

  22. Z. A. Podlubnaya, I. Ya. Podol’skii, M. D. Shpagina, and L. G. Marsagishvili, Biophysics 51, 701 (2006).

    Article  Google Scholar 

  23. I. M. Marusenko, Ya. A. Avdeeva, and I. I. Pol’skaya, Sovrem. Revmatol., No. 3, 50 (2009).

  24. R. Gordon, I. Podolski, E. Makarova, et al., J. Alzheimers Dis. 58, 711 (2017).

    Article  CAS  Google Scholar 

Download references

ACKNOWLEDGMENTS

The authors are grateful to A. Borisenkova for the samples of fullerenol provided.

Funding

This study was supported by the Russian Foundation for Basic Research, project no. 15-29-00153a.

Author information

Authors and Affiliations

  1. St. Petersburg Institute of Nuclear Physics, National Research Center Kurchatov Institute, Gatchina, Russia

    A. D. Slobodina, O. I. Bolshakova, A. E. Komissarov, N. V. Surina, S. B. Landa, P. A. Melent’ev & S. V. Sarantseva

Authors
  1. A. D. Slobodina
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. O. I. Bolshakova
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A. E. Komissarov
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. N. V. Surina
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. S. B. Landa
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. P. A. Melent’ev
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. S. V. Sarantseva
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to S. V. Sarantseva.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Slobodina, A.D., Bolshakova, O.I., Komissarov, A.E. et al. Study of the Neuroprotective Properties of Fullerenol C60(OH)30 with a Model of Alzheimer’s Disease. Nanotechnol Russia 15, 212–217 (2020). https://doi.org/10.1134/S1995078020020184

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1134/S1995078020020184

Search

Navigation